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1. Introduction 
The glycoproteins present on the platelet mem- 
brane are considered to be of great importance to 
platelet activities [ 1,2]. 
Few pathological platelet membrane glycoprotein 
abnormalities are known and ,usually they result in 
disturbance of aggregation. The Glanzmann’s throm- 
basthenia is characterized by a defective mechanism 
of platelet aggregation induced by ADP, collagen and 
thrombin [3]. Decrease or even complete absence of 
glycoproteins II and one of the components (glyco- 
proteins IIIa and IIIb) which contribute to the band 
known as glycoprotein III in platelets of patients 
suffering from this disease, has been reported [4-61. 
Another pathological abnormality of platelet mem- 
brane glycoprotein is the Bernard-Soulier syndrome, 
which is characterized by reduced platelet adhesion 
to subendothelium. There is evidence that these 
platelets are abnormal in the distribution of glycopro- 
tein Ib and glycocalicin [7,8]. The exposed position 
of the membrane glycoproteins on the platelet surface 
puts them in a good position to act as acceptors for 
aggregating agents or other stimuli. The determina- 
tion of the steric location and availability of these 
glycoproteins is, therefore, of major importance and 
interest. We report here the design and use of a few 
reagents and methods to identify glycoproteins on 
platelet membrane. These reagents might be of utmost 
importance in the study of changes and defects in 
glycoproteins of platelet membrane and other cell 
membranes. 
2. Materials and methods 
2.1 . Platelet preparation 
Washed platelets were prepared as follows: Fresh 
human blood was drawn into ACD anticoagulant 
Elsevier/North-Holkmd Biomedical Press 
(1.5 : 10) and centrifuged at room temperature at 
50 X g for 10 min. The PRP (platelet-rich plasma) 
obtained was centrifuged at 150 X g for 10 min to 
yield a platelet pellet. This pellet was resuspended in 
modified Tyrode’s buffer (pH 7.2). 
2.2.3,5-Diiodo-L-tyrosine hydrazide 
(fig.la) 3,5diiodo-L-tyrosine, 1.065 g (2.5 mmol) 
was’suspended in 25 ml dry methanol and cooled to 
-5’C. SO& (1 ml) was added dropwise. The solu- 
tion became clear and was left at room temperature 
for 24 h, evaporated to dryness and the methyl ester 
was purified by column chromatography on silica gel 
and eluted with CHCla 70%, methanol 30%. The total 
yield was 70%. The product was >98% pure (according 
to nitrogen analysis, NMR and mass spectrometry). 
The methyl ester (1 mg) was dissolved in 100 ~1 DMF 
(dimethyl formamide) and exchanged with 0.5 mCi 
‘*‘I using ICI as catalyst [9]. To the reaction mixture 
IOO’pl saturated NaCl solution was added and the 
precipitated product was collected by centrifugation 
in a Beckman Microfuge. 
2.3. Preparation of the hydrazide 
The radioactive methyl ester (0.5 mg) was dissolved 
in 0.5 ml methanol, 50 ~1 hydrazine hydrate were 
added and the mixture heated to 65°C for 3 h. The 
methanol was evaporated, the excess of hydrazine 
removed in vacua and the hydrazide was purified by 
silica-gel column chromatography (elution with 5% 
methanol in methylene chloride). The compound 
co-migrated with a non-radioactive sample on thin- 
layer chromatography and, accordingly, was >95% 
pure. 
2.4. Diiodo-p-hydroxyphenyl acyl azide 
(a) Diiodo-p-hydroxyphenyl acetic acid : 5.84 g 
(38.4 mmol) of the p-hydroxyphenyl acetic acid 
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were dissolved in 840 ml HQ 1 N and cooled to 
3°C. Asolutionofg=S g ICI + 5.5 gKI0a in 150mI 
water was added dropwise. The brown precipitate 
obtained was filtered off, dissolved in 400 ml 
sodium bicarbonate (pH 8) and precipitated by 
acidification to pH 1 with concentrated HCl. 
(b) ~~odo-hydroxyphenyl acetic acid methyl ester: 
6.5 g diiodo acid were dissolved in SO ml dry 
methanol containing 2ml thionyl chloride, and 
left overnight at room temperature. After evapota- 
tion and three washings with methanol, the pale 
yellow product was washed with water and dried. 
(c> ~odo-~-hydroxy~henyl acyl hydra~de was pre- 
pared as described for 3,S-d~odo-~-tyrosi~e 
hydrazide (figlb). 
(d) Diiodo-p-hydroxyphenyl acyl azide: prepared and 
used in situ as above (flg.lc). 
The platetet suspension was treated with sodium 
periodate at 0.1-20 mM for 10 min at 10°C and then 
reacted with the hydrazide derivative at S mM and 
incubated at 5°C for 15 min. Sodium cyanoboro- 
hydride was added to 5 mM final cont. and the 
platelet suspension was incubated for another 10 min 
at room temperature. 
2.6. Labelling with NaB3ff4 (sodium barohydtide) 
Platelet suspension was treated with various con- 
centrations of sodium periodate (0.2-20 mM) for 
10 min at lO*C. After ~e~trjfu~ng and removing 
excess of the sodium periodate, the platelet suspension 
in saline containing 1 mM EDTA was treated with 
NaBsl& (7 Ci/mmol) at 3 X lo-’ M final cont. for 
1 S nun at room temperature. Control experiments 
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were done by reducing platelets with unlabelled 
NaBH4 before the periodate oxidation or by omitting 
the periodate oxidation. 
2.7. Labelling with diiodo-p-hydroxyphenyl acyl azide 
Diiodo-p-hydroxyphenyl acetyl hydrazide, 2 mg/ 
100 pl(50 mM) in 0.1 N HCl, were cooled to O’C and 
treated with 0.1 M (final cont.) of sodium nitrite for 
15 min. The solution was neutralized to pH 7.4 with 
sodium bicarbonate. This mixture (10 ~1) was added 
to 750 1.11 platelet suspension in modified Tyrode’s 
solution and the incubation was continued for 15 min 
at IO’C. The platelets were centrifuged in a Beckman 
Microfuge and the pellet was washed twice with saline 
containing 1 mM EDTA. 
Exchange of unlabelled iodine with r2’I was carried 
out, using ICI as a catalyst [9]. 
SDS-polyacrylamide gel electrophoresis was done 
as in [IO]. All gels were under reduced conditions. 
NaB3H4 (7 Ci/mmol) and r2’I as KI carrier-free 
were purchased from Radiochemical Centre, 
Amersham. 3,4-Diiodo-L-tyrosine and p-hydroxy- 
phenyl acetic acid were purchased from Sigma. Silica 
gel (kieselgel 60, 70-230 mesh) was purchased from 
Merck. Fluorography was done as in [ 1 I]. 
3. Results 
3.1. Synthesis of labelling reagents 
The various synthetic routes are described in fig.1. 
It is clear that the various steps involve fairly simple 
organic chemistry methods which produce very useful 
reagents. 
3.2. Periodate oxidation 
This method, developed in [17], is based on the 
difference in reactivity of various vicinal hydroxyl 
groups. The two hydroxyls on the sialic acid side chain 
are very sensitive to such oxidation and, therefore, 
the formation of aldehyde can be achieved in a very 
selective way. This aldehyde can be reduced, e.g., 
with NaB3H4, to produce the radioactive alcohol 
derivative of the sialic acid and the glycoprotein. It 
can also be reacted with the hydrazide derivative to 
form the labile Schiff base, which is stabilized by 
mild reduction with sodium cyanoborohydride. In 
both cases the end product is a modified glycoprotein 
which is labelled either by tritium or by iodine. 
3.3. Labelling of membrane glycoproteins with acyl- 
hydrazide derivatives 
3,5-Diiodo-L-tyrosine hydrazide proved to be a 
very convenient labelling compound and its synthesis 
was quite easy. When this reagent was reacted with 
whole platelets pretreated with 1 mM sodium perio- 
date, a clear and specific labelling was obtained of a 
polypeptide having a Mr 150 000, probably glycopro- 
tein I. When the periodate-treated platelets were 
reduced with NaB31&, a completely different labelling 
pattern was obtained: mainly two polypeptides having 
Mr -100 000. These might be glycoprotein IIIa and 
IIIb (fig.2). 
4. Discussion 
The labelling of platelet membrane glycoprotein 
described above is based on the same principle as the 
PAS staining, namely, the oxidation of vicinal 
hydroxyls with periodate, followed by a Schiff base 
formation. Use of the radioactive reagents increases 
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Fig.2. SDS-polyacrylamide eiectrophoresis and autoradio- 
grams of labelled platelets: (1) Coomassie Blue staining of 
washed human platelets; (2) autoradiogram of whole platelets 
labelled with 3,5diiodo-L-tyrosine hydrazide; (3) autoradio- 
gram of whole platelets labelled with NaB’H, after 20 mM 
periodate treatment; (4) same as (3) but the platelets were 
reduced with NaBH, (non-labelled) before the periodate 
treatment; (5) same as (3) but 0.1 mM periodate; (6) auto- 
radiogram of whole platelets labelled with diiodo-p-hydroxy- 
phenyl acyl aside. 
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the sensitivity over the conventional PAS methods. In 
addition, these methods enabled us to identify various 
membrane glycoproteins in the intact cell. The method 
of periodate oxidation, followed by NaB3H4 reduc- 
tion, has been used in the past for the labelling of 
glycoproteins [ 12-141. The various sugars exhibit 
different sensitivities towards periodate oxidation, 
sialic acid being one of the most sensitive, a fact that 
makes it possible to selectively label glycoproteins 
containing this acid. 
Preparation of [1251] tyrosine hydrazide, through 
the methyl ester, is very simple and results in a highly- 
polar compound, which will not easily penetrate the 
membrane lipid bilayer. The fact that the hydrazine 
is not directly attached to the aromatic ring only 
stabilizes the Schiff base formed and will thus increase 
the yield. 
We used very low periodate concentrations (O.l- 
2 mM) for glycoprotein labelling, compared to those 
used in [14] or [12] (5-10 mM and 3-4 mM, res- 
pectively). Our results indicate that the periodate 
concentration had no effect on the labelling pattern. 
Two different labelling patterns were obtained when 
platelets were labelled with NaB3b or di[“‘I]iodo- 
tyrosine hydrazide (tig.2). It is clear, therefore, that 
in both cases oxidation of sialic acid on glycoprotein I 
and glycoprotein III occurred. However, 3,5-diiodo- 
L-tyrosine hydrazide reacted mainly with the aldehyde 
groups formed on glycoprotein I, while NaB3H4 
reduced mainly the aldehydes formed on glycopro- 
tein III. It is possible that the differences in labelling 
are a result of the electrical and charge environment 
of the glycoproteins. While NaB3H4 reduction pro- 
ceeds through a hydride ion 3H-, i.e., a negative 
species, the interaction of the oxidized glycoprotein 
with 3,5-diiodo-L-tyrosine hydrazide is via the posi- 
tively-charged hydrazide group. Therefore, it is 
possible that the immediate environment of glyco- 
protein III is less negative than that of glycoprotein I. 
This difference in electrical charge of the two glyco- 
proteins might result from the presence of a high con- 
centration of sialic acid on glycoprotein I [ 151. 
Comparison of these labellings with that by diiodo- 
p-hydroxyphenylacyl azide, which will label proteins 
via e-amino lysine groups, is shown in fig.2. No 
labelling of glycoproteins is obtained, but rather two 
proteins between Mr 200 000-260 000 are highly 
labelled. 
We have shown that by proper design of the 
labelling reagent one can selectively label the glyco- 
proteins on the platelet membrane. These labelling 
reagents are suitable for any glycoprotein and may, 
therefore, be used to label any other membrane glyco- 
proteins in other cells. 
Acknowledgements 
The generous financial support of the Gatsby 
Foundation (London) is highly appreciated. A. R. is 
incumbent of the Samuel and Isabelle Friedman 
career development chair. 
References 
[I] Okumura, T. and Jamieson, G. A. (1976) Thromb. 
Res. 8,701-705. 
[2] Nurden, A. T. and Caen, J. P. (1976) Thromb. 
Haemosta. 35, 139. 
[41 
I51 
[61 
[71 
[ 3 ] Caen, J. P., Castalchi, P. A., Leclerc, J. C., Inceman, S., 
Larrieu, M. J., Probst, M. and Bernard, J. (1966) Am. J. 
Med. 41,4-26. 
Bolin, R. B., Okumura, T. and Jamieson, G. A. (1977) 
Nature 269,69-70. 
Nurden, A. T. and Caen, J. P. (1974) Brit. J. Haematol. 
28,253-260. 
Nurden, A. T. and Caen, J. P. (1969) Semin. Hematol. 
16,234-250. 
PI 
191 
[lOI 
[Ill 
1121 
1131 
1141 
iI51 
Caen, 3. P., Nurden, A. T., Jeanneau, C., Michel, H., 
Tobelem, G., Levi-Toledano, S., Sultan, Y., Valensi, F. 
and Bernard, J. (1966) J. Lab. Clin. Med. 87,586-596. 
Jenkins, C. S. P., Phillips, D. R., Clemetson, K. J., 
Meyer, D., Larrieu, M. J. and Luscher, E. F. (1976) 
J. Lab. Clin. Invest. 57,112-124. 
Helmkamp, R. W. and Sears, D. S. (1970) Int. J. Appl. 
Radiat. Isot. 21,683-685. 
Laemmli, U.K. (1970) Nature 227,680-685. 
Bonner, W. M. and Laskey, R. A. (1974) Eur. J. Bio- 
them. 46,83-88. 
Van Lenten, L. and Ashwell, G. (1971) J. Biol. Chem. 
246,1889-1894. 
Sharon, N. and Lis, H. (1972) Science 177,949-959. 
Lotan, R., Debray, H., Cacan, R. and Sharon, N. (1975) 
J. Biol. Chem. 250, 1955-1957. 
Nurden, A. T. and Caen, J. P. (1975) Nature 255, 
720-722. 
88 
